國家衛生研究院 NHRI:Item 3990099045/9359
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 907685      Online Users : 946
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9359


    Title: Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation
    Authors: Lee, TY;Lin, JT;Zeng, YS;Chen, YJ;Wu, MS;Wu, CY
    Contributors: Division of Health Services and Preventive Medicine
    Abstract: Radiofrequency ablation (RFA) is the best choice for curative treatment of hepatocellular carcinoma (HCC) cases not suitable for surgical intervention, but efforts should be made to reduce the risk of tumor recurrence. We aimed to investigate the association between nucleos(t)ide analogue (NA) therapy for hepatitis B virus (HBV) and the risk of HCC recurrence following RFA. Using the Taiwan National Health Insurance Research Database between July 1, 2004 and December 31, 2012, we screened 48,807 patients with newly diagnosed HBV-related HCC. We identified 850 patients (200 patients who used NAs for more than 90 days and 650 patients who never used NA after RFA) who received RFA as a potentially curative treatment for HCC. Patients in the NA-treated cohort were randomly matched 1:2 with patients in the untreated cohort by age, gender, cirrhosis, and the time period between RFA and initiation of NA therapy. Finally, 133 patients were recruited in the NA-treated group and 266 in the untreated group for analysis. Cumulative incidences of and hazard ratios (HRs) for HCC recurrence were analyzed after adjusting for competing mortality. The HCC recurrence rate of the NA-treated group was significantly lower than that of the untreated group (2-year recurrence rate: 41.8%, 95% confidence interval [CI]: 32.9-50.6% vs. 54.3%, 95% CI: 48.0-60.6%; modified log-rank test P< 0.05). In modified Cox regression analysis, NA therapy was independently associated with a decreased risk of HCC recurrence (HR 0.69, 95% CI: 0.50-0.95; P< 0.05). Multivariate stratified analyses verified the association of NA therapy and decreased HCC recurrence in almost all patient subgroups. CONCLUSION: NA therapy was associated with a decreased risk of HCC recurrence among patients with HBV-related HCC following RFA.
    Date: 2016-05
    Relation: Hepatology. 2016 May;63(5):1517-1527.
    Link to: http://dx.doi.org/10.1002/hep.28266
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0270-9139&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000374738000015
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84951934194
    Appears in Collections:[Jaw-Town Lin] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB26426978.pdf1198KbAdobe PDF542View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback